Publications scientifiques

Auteurs : Rivière A, Picard C, Berastegui C, Mora VM, Bunel V, Godinas L, Salvaterra E, Rossetti V, Savale L, Israel-Biet D, Demant X, Bermudez J, Meloni F, Jaksch P, Magnusson J, Beaumont L, Perch M, Mornex JF, Knoop C, Aubert JD, Hervier B, Nunes H, Humbert M, Gottlieb J, Uzunhan Y, Le Pavec J.

Sources : Am J Transplant. 2022 Dec;22(12):2990-3001.

Dilatation des bronches (DDB) ou Bronchectasie (non CF, non DCP) Fibrose pulmonaire idiopathique (FPI) Hypertension pulmonaire (HTP) Maladies pulmonaires chroniques kystiques (LAM/MKPM) Pneumopathies interstitielles diffuses (PID) Sarcoïdose

[Updated indications and contraindications in 2022 for lung transplantation in France].

Auteurs : Le Pavec J, Pison C, Hirschi S, Bunel V, Mordant P, Brugière O, Le Guen M, Olland A, Coiffard B, Renaud-Picard B, Tissot A, Brioude G, Borie R, Crestani B, Deslée G, Stelianides S, Mal H, Schuller A, Falque L, Lorillon G, Tazi A, Burgel PR, Grenet D, De Miranda S, Bergeron A, Launay D, Cottin V, Nunes H, Valeyre D, Uzunhan Y, Prévot G, Sitbon O, Montani D, Savale L, Humbert M, Fadel E, Mercier O, Mornex JF, Dauriat G, Reynaud-Gaubert M.

Sources : Rev Mal Respir. 2022 Dec;39(10):855-872.

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON.

Auteurs : Allanore Y, Vonk MC, Distler O, Azuma A, Mayes MD, Gahlemann M, James A, Kohlbrenner V, Alves M, Khanna D, Highland KB; SENSCIS-ON trial investigators.

Sources : Ann Rheum Dis. 2022 Dec;81(12):1722-1729.

Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease.

Auteurs : Bay P, de Chambrun MP, Rothstein V, Mahevas M, De Prost N, Roux A, Zuber B, Biet DI, Hervier B, Tazi A, Mouthon L, Mekinian A, Deligny C, Borie R, Meurice JC, Meyer A, Priou P, Savale L, De Saint Martin L, Gallay L, Cottin V, Blanchard E, Brillet PY, Khafagy P, Benveniste O, Nunes H, Allenbach Y, Uzunhan Y.

Sources : J Autoimmun. 2022 Dec;133:102941.

Frequency and predictors for chronic thromboembolic pulmonary hypertension after a first unprovoked pulmonary embolism: Results from PADIS studies.

Auteurs : Fauché A, Presles E, Sanchez O, Jaïs X, Le Mao R, Robin P, Pernod G, Bertoletti L, Jego P, Parent F, Lemarié CA, Leven F, Le Roux PY, Salaun PY, Nonent M, Girard P, Lacut K, Savale L, Mélac S, Guégan M, Mismetti P, Laporte S, Leroyer C, Montani D, Couturaud F, Tromeur C; PADIS-PE Investigators.

Sources : J Thromb Haemost. 2022 Dec;20(12):2850-2861.

Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis.

Auteurs : Hlavaty A, Roustit M, Montani D, Chaumais MC, Guignabert C, Humbert M, Cracowski JL, Khouri C.

Sources : Br J Clin Pharmacol. 2022 Dec;88(12):5227-5237.

Interest of TAPSE/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment.

Auteurs : Fauvel C, Raitiere O, Boucly A, De Groote P, Renard S, Bertona J, Lamblin N, Artaud-Macari E, Viacroze C, Schleifer D, Dominique S, Pichon J, Jais X, Montani D, Sitbon O, Savale L, Humbert M, Bauer F.

Sources : J Heart Lung Transplant. 2022 Dec;41(12):1761-1772.

Anomalies du développement pulmonaire (ADP)

Elexacaftor/Tezacaftor/Ivacaftor Disrupts Respiratory Tract Development in a Murine Fetal Lung Explant Model

Auteurs : Lhuillier M, Aoust L, Dreano E, Franco-Montoya ML, Landry-Truchon K, Houde N, Chhun S, Hinzpeter A, Edelman A, Delacourt C, Jeannotte L, Sermet-Gaudelus I, Hadchouel A

Sources : Am J Respir Cell Mol Biol. 2022 Dec;67(6):723-726.

Clinical and molecular analysis of lung cancers associated with fibrosing interstitial lung disease.

Auteurs : Héluain V, Prévot G, Cabarrou B, Calvayrac O, Taranchon-Clermont E, Didier A, Tabourier-Gouin S, Milia J, Mazières J.

Sources : Respir Med Res. 2022 Nov 30;83:100946.

The evolving landscape of pulmonary arterial hypertension clinical trials.

Auteurs : Weatherald J, Boucly A, Peters A, Montani D, Prasad K, Psotka MA, Zannad F, Gomberg-Maitland M, McLaughlin V, Simonneau G, Humbert M; Evolving Landscape of Pulmonary Arterial Hypertension and Redesigning Pulmonary Arterial Hypertension Clinical Trials Task Force of the 18th Global CardioVascular Clinical Trialists Forum.

Sources : Lancet. 2022 Nov 26;400(10366):1884-1898.